DigestAI news desk

Cut through the AI noise.

Research

AI transforms radiotherapy workflows while clinical adoption lags

Artificial intelligence is reshaping radiation oncology by automating routine tasks such as auto‑contouring, dose calculation, quality assurance and outcome prediction. A growing portfolio of commercially available and FDA‑approved tools is already in use, and many clinical trials are evaluating their technical performance and safety.

1 source primary source

Key points

  • AI automates contouring, dose calculation, quality assurance and outcome prediction, with many FDA‑approved tools now available.
  • Clinical rollout is slowed by technical, ethical, legal and data‑bias concerns despite ongoing trials.
  • Emerging generative AI, foundation models, digital twins and agentic AI promise next‑generation radiotherapy planning.

Despite these advances, widespread clinical deployment remains limited. Technical integration challenges, ethical and legal concerns, data‑bias risks and the need for expert oversight are repeatedly cited as barriers. Researchers highlight that emerging technologies—generative AI, foundation models, digital twins and agentic AI—could enable more personalized, adaptive treatment planning, potentially defining the next era of radiotherapy.

The review stresses that responsible adoption will require robust validation, transparent governance and clear regulatory pathways to translate AI’s promise into routine patient care.

Read the original at Nature Machine Learning primary sourceOpen source ↗
Topics · follow one to build your own front page
AbbvieBristol-Myers SquibbPfizeriRAI TechnologiesE. KatsoulakisI. El NaqaE. K.

The headline, key points and digest above were generated by Digest AI's editorial model from the linked sources. Automated summaries can contain errors: the sources are the record. Spotted a mistake? Tell us. Published by Martin K., who runs Digest AI and handles corrections.

Comments

via GitHub Discussions

More in Research

All →

Related stories